Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells 87,507 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 87,507 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $36.81, for a total transaction of $3,221,132.67. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $147,240. This represents a 95.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Simrat Randhawa also recently made the following trade(s):

• On Friday, November 14th, Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34.

Dianthus Therapeutics Trading Up 15.1%

DNTH traded up $5.35 on Friday, hitting $40.85. The company had a trading volume of 1,574,910 shares, compared to its average volume of 505,087. The firm has a market cap of $1.75 billion, a P/E ratio of -11.74 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $41.15. The company’s fifty day moving average price is $35.94 and its 200 day moving average price is $25.62.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.58 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. lifted its stake in shares of Dianthus Therapeutics by 686.4% in the 3rd quarter. Raymond James Financial Inc. now owns 11,245 shares of the company’s stock worth $442,000 after acquiring an additional 9,815 shares during the period. Acuta Capital Partners LLC acquired a new position in shares of Dianthus Therapeutics during the third quarter worth about $984,000. Balyasny Asset Management L.P. purchased a new position in Dianthus Therapeutics during the third quarter worth about $17,460,000. Longaeva Partners L.P. acquired a new stake in Dianthus Therapeutics in the third quarter valued at about $984,000. Finally, Brooklyn Investment Group acquired a new stake in Dianthus Therapeutics in the third quarter valued at about $262,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Truist Financial initiated coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 14th. They set a “buy” rating and a $56.00 price objective for the company. Raymond James Financial reissued an “outperform” rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. Robert W. Baird raised their price target on Dianthus Therapeutics from $50.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, September 9th. Finally, Wedbush upped their price objective on Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $63.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.